SGN-15 / Pfizer - LARVOL DELTA

Effect of bacterial glycosyltransferases on resistance to Lewis Y-targeting antibody-drug conjugates. (ASCO 2025) - "This study provides the first evidence that bacterial glycosyltransferases in the TME may interfere with ADC efficacy, potentially contributing to failure of LeY-targeting ADCs such as SGN-15 in NSCLC. Mimicry of human fucosyltransferases by bacterial enzymes reveals a novel resistance mechanism that builds on prior literature implicating H pylori in Lewis antigen modulation. These findings underscore the global relevance of tumour-associated bacterial ecosystems in shaping cancer treatment outcomes and suggest geographic variability in tumour microbiome composition may influence ADC efficacy."

Infectious Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Using a Monoclonal Antibody Plus Chemotherapy in Patients With DLBCL : Episode 7: Treatment Considerations in Primary Refractory vs Early-Relapsed DLBCL - "In the first article of a 2-part series, Joseph M. Tuscano, MD, discusses at a virtual live event with fellow clinicians how to define early-relapsed or primary refractory diffuse large B-cell lymphoma and how this impacts treatments for this patient population."

Jonathan Coleman, MD, on Neoadjuvant Chemo for Upper-Tract Urothelial Carcinoma - First and only fully accrued prospective study of the treatment for such high-risk patients (MedPageToday) - "Coleman: In short, persistence, evidence, and collaboration. It took nearly a year of repeated discussions with investigators and a relentless effort to develop a trial that was felt to be clinically meaningful and acceptable....The fuel for the journey was the excellent support for clinical research at MSK, a great mentor in Dr. Dean Bajorin, and our amazing, dedicated patients who put their trust in us to try to get them a better outcome with a well-developed, clinically important study."

Interview

Post-procedure Hyponatremia in Patients Undergoing Liver Embolotherapy for Neuroendocrine Tumor Metastases (SIO 2023) - "Hyponatremia was a common complication of embolotherapy for patients with NETLM. Mild hyponatremia did not significantly prolong hospital stays. However, hyponatremia that warranted medical intervention (Na<130) resulted in significant prolongation of the length of hospital stay, was commonly due to SIADH, and was associated with severe post-procedural nausea that necessitated the use of at least three different classes of antiemetic medications."

Oncology Grand Rounds: Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas (MedPageToday) - P=NA | N= NA | SWOG-8710 trial (NCT02756637) | "Muscle-invasive bladder cancer (MIBC) is a biologically aggressive disease with propensity for early distant and locoregional metastases....Nevertheless, patients with MIBC routinely pose dilemmas because of comorbidities, advanced age, frailty, side effects of treatment, kidney insufficiency, etc."

Clinical data

Cardio-Oncology: From Adverse Outcome Pathways to Cardiotoxicity Mitigation (Sciforum) - "12:10 PM - 12:40 PM, Doxorubicin-Induced Cardiomyopathy: From Mitochondria to Clocks."

Live event • Cardiomyopathy

Use of Inhibitor Combination Based on MSI Status in Endometrial Cancer (Targeted Oncology) - "P3 | N= NA| KEYNOTE-775 (NCT03517449)| Sponsor: Eisai Inc.| "Bhavana Pothuri, MD...discusses the results of the KEYNOTE-775 trial (NCT03517449) in patients with advanced endometrial cancer in relation to microsatellite instability (MSI) status. According to Pothuri, the randomized phase 3 KEYNOTE-775 trial of pembrolizumab (Keytruda) and lenvatinib (Lenvima) showed superior progression-free survival (PFS) and overall survival (OS) versus doxorubicin or paclitaxel in patients who had been previously treated with platinum-based chemotherapy. However, the combination of pembrolizumab and lenvatinib was approved for patients without MSI-high (MSI-H) status or a mismatch repair deficiency (dMMR) based on the study results."

Video

A 64-Year-Old Woman With Advanced Endometrial Carcinoma - Episode 5: Treating Advanced Endometrial Carcinoma: Counseling on Safety Profiles (Targeted Oncology) - "Robert L. Coleman, MD, FACOG, FACS: Adverse events are very important to consider when choosing a regimen. Every counseling session that I go through with a patient, when we're going to start a new therapy or are already on therapy, we review those adverse events so that they're clear and known to the patient for their expectations. One of the most important reasons to do this, other than to provide a thorough counseling for the patient, is that it allows us to navigate through events that might discontinue treatment. As you could imagine, patients who are off therapy aren't likely to benefit. We try to provide the expectation for these so that it can be navigated in an effort to keep patients on treatment."

Video

Seagen to Highlight Multiple ADCETRIS (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting (Businesswire) - “Seagen Inc....announced that new data for ADCETRIS® (brentuximab vedotin), including five oral presentations, will be featured at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021. Data presentations will include updated safety and efficacy results from clinical trials examining the potential of ADCETRIS with novel combinations in patients with advanced stage classical Hodgkin lymphoma (HL), in patients with newly diagnosed CD30-expressing peripheral T-cell lymphoma (PTCL) and in patients with other histologies.”

Clinical data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Oncology • Peripheral T-cell Lymphoma

Bladder cancer: positive results for two targeted therapies and neoadjuvant chemotherapy [Google translation] (Medscape) - "During the virtual congress of the European Society of Medical Oncology (ESMO 2021), Dr Laurence Albiges...summarized and commented on the results of three trials presented the day before, during a session devoted to urogenital cancers , excluding prostate."

Media quote

ESMO 2021: VESPER Trial Indicates Neoadjuvant Dose-Dense MVAC Should be Standard of Care in Muscle Invasive Bladder Cancer (PracticeUpdate) - P3, N=500; VESPER (NCT01812369); "All patients met cisplatin therapy criteria. For patients receiving neoadjuvant chemotherapy, disease was defined as ≥ T2, N0, and M0, while patients who received adjuvant chemotherapy had disease defined as > pT2 or pN+ and M0....'The VESPER trial is potentially practice-changing and supports the use of dose-dense MVAC as the most active regimen in the neoadjuvant approach to muscle invasive bladder cancer, with an acceptable, in my opinion, cost in toxicity,' said Enrique Grande, MD, PhD...during a discussion following the presentation."

P3 data

IASLC WCLC 2021: Lurbinectedin-Doxorubicin a Safer Option for Relapsed Small Cell Lung Cancer Than Standard-of-Care Chemotherapy (PracticeUpdate) - "'We did not see an improvement in efficacy, and the trial did not meet the primary endpoint,' concluded Dr. Paz-Ares. 'However, we did confirm the safety profile [of lurbinectedin], even when adding doxorubicin. Lurbinectedin [was more tolerable], particularly in terms of myelosuppression, than standard of care. More importantly, new combinations of lurbinectedin and other cytotoxic agents are currently being explored in this setting.'"

Media quote

ATLANTIS Results: Lurbinectedin Plus Doxorubicin in SCLC (Medscape) - "Paz-Ares believes that, taken together, the results 'support the clinical benefit of lurbinectedin' in the second-line treatment of SCLC....Rudin...continued that there were nevertheless some 'positive outcomes from this negative trial.'...Turning to the 'inevitable coulda, shoulda, woulda for this clinical trial,' Rudin said, 'unfortunately, we have to acknowledge that ATLANTIS joins the ranks of negative trials in patients with recurrent small cell lung cancer.'...Over on Twitter, Stephen V. Liu, MD...said the key issue with ATLANTIS is 'it probably did not ask the question we wanted answered.'"

Media quote

Immunotherapies Continue to Show Intriguing Benefit in Cisplatin-Ineligible Metastatic Urothelial Cancer (OncLive) - "'Maintenance therapy with avelumab in [patients with] responding or stable disease after 4 to 6 cycles of gemcitabine/platinum therapy should be considered practice-changing,' said Sonpavde. 'Where the debate arises in terms of the role of this regimen [within the] paradigm is in cisplatin-ineligible patients who are PD-L1-high. What do we do with these patients? This is a discussion to be had with the patient. This is shared decision-making and patients drive [the decision] based on the information they receive'....In an interview with OncLive® during an International Perspectives on Cancer webinar on Genitourinary Cancers, Sonpavde...discussed trials of interest for both cisplatin-eligible and -ineligible patients with metastatic urothelial cancer, as well as other agents coming down the pipeline."

Interview • Media quote

Combinations and T-Cell Engagers Push Myeloma Paradigm Forward (OncLive) - "'There has been such a breadth of new data coming out in the non-CAR T-cell therapy setting for relapsed disease,' said Ailawadhi. 'The bottom line is we are not going to be using drugs as single agents; that is not where the benefit [of these agents] lies in multiple myeloma. [Also,] although the initial CAR T-cell therapy data have given us extremely good signals, T-cell engagers may provide an alternative [option]. Immunotherapy for myeloma has finally arrived.'"

Interview • Media quote

A 72-Year-Old Man With Heavily Pretreated, Relapsed/Refractory Multiple Myeloma - Episode 2: Treatment Options for Heavily Pretreated RRMM (YouTube) - "Hydration, energy, fatigue, and asthenia are all adverse effects that persist and require interventions with additional supportive care measures. It's clear that both belantamab mafodotin and selinexor have significant activity in the population of patients with refractory myeloma. If patients can tolerate therapy, they may gain significant clinical benefit, but the idea of trying to anticipate and manage the potential adverse events is quite different between these 2 approved agents in the context of refractory myeloma."

Video

Multiple Myeloma in the African American Community (Verywell Health) - "Research shows that disparities in multiple myeloma survival within the African Community stem from inferior treatment utilization and access rather than underlying pathogenesis. Innovative and multidisciplinary approaches are urgently needed to enhance our understanding of the many disparities that exist at each stage of the multiple myeloma disease continuum to facilitate the elimination of these disparities."

Online posting

Dr. Brufsky on the risk COVID-19 poses to patients with cancer (OncLive) - "Adam M. Brufsky, MD, PhD, discusses the risk the coronavirus disease 2019 poses to patients with cancer....Individuals who have previously completed chemotherapy or are on active hormonal therapy are unlikely to be at an increased risk of developing severe complications from COVID-19, explains Brufsky. Conversely, patients who are on active chemotherapy, are older, have diabetes or hypertension, or are men, are at greater risk."

Video

Neoadjuvant durvalumab regimen improves responses in triple-negative breast cancer (Targeted Oncology) - P1/2, N=71; NCT02489448; "A phase I/II study demonstrated that the addition of durvalumab in the neoadjuvant setting to nab-paclitaxel (Abraxane), doxorubicin, and cyclophosphamide-induced an improvement in pathologic complete response (pCR) rates compared with historical chemotherapy controls for patients with triple-negative breast cancer (TNBC)...The pCR rate observed in the 55 patients treated with the durvalumab regimen was 44% (95% CI, 30%-57%). Among patients with TNBC who had positive PD-L1 expression in their tumors, the pCR rate was 59% (95% CI, 0.39-0.76)....The regimen was also well-tolerated, demonstrating no unexpected adverse events (AEs)."

P1/2 data • Breast Cancer • Oncology • Triple Negative Breast Cancer

Neoadjuvant durvalumab regimen improves responses in triple-negative breast cancer (Targeted Oncology) - "In an interview...Lajos Pusztai...discussed the findings from the phase I/II clinical trial of durvalumab in combination with concurrent nab-paclitaxel and doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with triple-negative breast cancer....Pusztai: I think this study adds an additional piece of evidence to this building wall that suggests that immunotherapy will make a major impact in the treatment of TNBC. There are 3 randomized trials that have shown an improvement in the pCR. Some studies were statistically significant and some were just barely missing the significance levels but were still supporting....Tumor mutational burden is in the pipeline, as well as various gene signatures that integrate the information in a number of genes besides PD-L1."

Interview

Triple-drug therapy produces response in triple-negative breast cancer, mouse study shows (Oncology Nurse Advisor) - "EAD [doxorubicin, all-trans retinoic acid (ATRA), entinostat] significantly reduced the size of triple-negative breast cancer tumors in mice and reduced the number of lab-grown spheres of metastatic breast cancer cells harvested from patients and grown in the laboratory...Compared to the combination of only entinostat and doxorubicin, EAD reduced by twofold the number of tumor-starting cells in the tumor spheres..."

Preclinical • Breast Cancer • Oncology

NantOmics to report data on cardiac function in sarcoma patients receiving aldoxorubicin with doxorubicin equivalent doses over 1000 mg/m2 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting (Businesswire) - "A total of 52 patients were enrolled in three phases of the study and results found that in 11 patients [with sarcoma], the median cumulative doxorubicin dose prior to aldoxorubicin treatment was 158 mg/m2....As a result, no patient developed any sign or symptom of clinical congestive heart failure. Ventricular ejection fractions ranged from 45-74% baseline, and 50-77% at end of treatment, median being 60% both at the beginning and end of treatment. The study shows that aldoxorubicin lacks cardiotoxicity in patients treated with aldoxorubicin alone or in combination with ifosfamide/mesna. No evidence of cardiac toxicity of aldoxorubicin up to doxorubicin equivalent dose of 7500mg/m2."

Clinical data • Oncology • Sarcoma